Biofrontera Reports Strong Q1 2026 Results
Biofrontera Inc. (NASDAQ: BFRI) delivered robust first-quarter 2026 financial performance, with product revenues reaching $10.1 million, a 17% increase from $8.6 million in the prior-year quarter. This growth stems from a 16% rise in Ameluz units sold and a price adjustment implemented in Q4 2025.
CEO, President, and Chairman Hermann Lubbert stated, “The first quarter of 2026 marks the first full quarter under our new cost structure following the Strategic Transaction, and the results speak clearly. Revenue grew 17% year over year, gross margins expanded to approximately 80%, and our cash consumption was near zero—a dramatic improvement from $4.1 million of cash consumption in the prior-year quarter.”
Improved Gross Margins and Cost Efficiency
Gross margins climbed to about 80% in Q1 2026, up 18 percentage points from 62% a year earlier. This expansion reflects the shift to a lower earnout structure after the October 2025 Strategic Transaction with Biofrontera AG, which reduced related-party cost of revenues by approximately 40% year over year.
Financial Highlights
- Operating expenses totaled $14.4 million, compared to $13.1 million in Q1 2025.
- Selling, general, and administrative expenses rose to $11.0 million from $8.7 million, driven by higher marketing costs and legal fees.
- Research and development expenses fell to $0.9 million from $1.2 million as clinical trials near completion.
- Net loss stood at $4.8 million, or $0.41 per share, versus $4.2 million, or $0.47 per share, last year.
- Cash balance remained steady at $6.3 million as of March 31, 2026, down slightly from $6.4 million at year-end 2025.
- Operational cash use was minimal at $70,000, a sharp reduction from $4.1 million previously.
- Adjusted EBITDA improved to $(3.6) million from $(4.4) million.
2026 Outlook and Pipeline Progress
Management targets cash flow breakeven in 2026 while pursuing gross margins of 80% to 85%. Lubbert emphasized, “We remain focused on our goal of reaching sustained profitability and cash-flow breakeven while setting the foundation for medium to long-term growth.”
Key advancements include FDA acceptance of the Ameluz sNDA for superficial basal cell carcinoma, with a PDUFA date of September 28, 2026. Positive Phase 3 data for actinic keratoses on extremities, neck, and trunk met primary endpoints, and Phase 2b acne vulgaris results showed a 58% lesion reduction.
Biofrontera also regained Nasdaq minimum bid price compliance on May 6, 2026.
